Cancers, Vol. 16, Pages 1456: A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid Tumors

Conclusions: Dual targeting of Aurora A kinase and mTOR resulted in marginal clinical benefit in a population of patients with refractory solid tumors, including pancreatic adenocarcinoma, though individual patients experienced significant response to therapy. Correlatives indicate apoptotic response and tumor immune cell infiltrate may affect clinical outcomes.

Source: Cancers - April 10, 2024 Category: Cancer & Oncology Authors: S. Lindsey Davis Wells A. Messersmith W. Thomas Purcell Elaine T. Lam Bradley R. Corr Alexis D. Leal Christopher H. Lieu Cindy L. O ’Bryant Stephen G. Smoots Evan D. Dus Kimberly R. Jordan Natalie J. Serkova Todd M. Pitts Jennifer R. Diamond Tags: Article Source Type: research